Janux Therapeutics, Inc. financial data

Symbol
JANX on Nasdaq
Location
10955 Vista Sorrento Parkway, Suite 200, San Diego, CA
Fiscal year end
December 31
Latest financial report
10-Q - Q2 2025 - Aug 7, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 5.07K % +24.4%
Debt-to-equity 4.28 % -39%
Return On Equity -11.5 % -30.8%
Return On Assets -11 % -34.1%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 60.1M shares +15.2%
Common Stock, Shares, Outstanding 59.3M shares +13.7%
Entity Public Float 1.3B USD +365%
Common Stock, Value, Issued 59K USD +13.5%
Weighted Average Number of Shares Outstanding, Basic 61.9M shares +13.7%
Weighted Average Number of Shares Outstanding, Diluted 61.9M shares +13.7%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 99.1M USD +86.7%
General and Administrative Expense 46.2M USD +65.2%
Operating Income (Loss) -145M USD -120%
Nonoperating Income (Expense) 39.2M USD +79.3%
Net Income (Loss) Attributable to Parent -106M USD -140%
Earnings Per Share, Basic -1 USD/shares -102%
Earnings Per Share, Diluted -1 USD/shares -102%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 52.4M USD +258%
Accounts Receivable, after Allowance for Credit Loss, Current 7.5M USD
Assets, Current 1.01B USD +51.9%
Property, Plant and Equipment, Net 4.69M USD -21.1%
Operating Lease, Right-of-Use Asset 18.5M USD -8.04%
Other Assets, Noncurrent 2.69M USD +2.01%
Assets 1.03B USD +49.3%
Accounts Payable, Current 3.48M USD +177%
Employee-related Liabilities, Current 2.35M USD +21.8%
Accrued Liabilities, Current 16M USD +87.1%
Contract with Customer, Liability, Current 0 USD -100%
Liabilities, Current 21.4M USD +85.2%
Contract with Customer, Liability, Noncurrent 0 USD -100%
Operating Lease, Liability, Noncurrent 20.3M USD -8.44%
Liabilities 41.7M USD +23.6%
Accumulated Other Comprehensive Income (Loss), Net of Tax 3.75M USD
Retained Earnings (Accumulated Deficit) -295M USD -55.8%
Stockholders' Equity Attributable to Parent 991M USD +50.6%
Liabilities and Equity 1.03B USD +49.3%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -17M USD -14.7%
Net Cash Provided by (Used in) Financing Activities 554K USD -99.8%
Net Cash Provided by (Used in) Investing Activities -340M USD -199%
Common Stock, Shares Authorized 200M shares 0%
Common Stock, Shares, Issued 59.3M shares +13.7%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Deferred Tax Assets, Valuation Allowance 66.7M USD +48.4%
Deferred Tax Assets, Gross 73.4M USD +39.5%
Operating Lease, Liability 22.2M USD -6.84%
Depreciation 519K USD -2.44%
Payments to Acquire Property, Plant, and Equipment 371K USD +88.3%
Lessee, Operating Lease, Liability, to be Paid 29.8M USD -10.4%
Property, Plant and Equipment, Gross 10.7M USD +8.37%
Operating Lease, Liability, Current 1.87M USD +14.9%
Lessee, Operating Lease, Liability, to be Paid, Year Two 3.72M USD +2.99%
Lessee, Operating Lease, Liability, to be Paid, Year One 3.61M USD +3.02%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 7.62M USD -19.3%
Lessee, Operating Lease, Liability, to be Paid, Year Three 3.83M USD +2.99%
Deferred Tax Assets, Operating Loss Carryforwards 25.7M USD +37%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 4.03M USD +68.7%
Lessee, Operating Lease, Liability, to be Paid, Year Four 3.95M USD +3%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 6.66M USD -12.9%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%